Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

 Plus Therapeutics (Nasdaq: PSTV) announces FDA's conditional acceptance of REYOBIQ™ as the proprietary name for its lead therapeutic candidate. REYOBIQ™ (rhenium Re186 obisbemeda) is currently under clinical investigation for treating Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM), both central nervous system (CNS) cancers.

The company must submit a request for proprietary name review when filing the marketing application (NDA). This branding initiative aims to help investigators, investors, and potential patients better connect with the rhenium-based radiotherapeutic beyond its chemical composition.

https://www.stocktitan.net/news/PSTV/plus-therapeutics-introduces-reyobiqtm-fda-accepted-proprietary-name-6lbr835y1ojh.html